Planta Med 2010; 76 - P93
DOI: 10.1055/s-0030-1251855

Inhibition of Human Monoamine Oxidase A and B by beta-Carboline Alkaloids: Structure Activity Relationship Analysis

ND Chaurasiya 1, I Muhammad 1, BL Tekwani 1, 2
  • 1National Center for Natural Products Research and
  • 2Department of Pharmacology, School of Pharmacy, University of Mississippi, University, Mississippi 38677, USA

The beta-carboline alkaloids are predominant constituents of several natural products including plants, marine and microbial sources. The psychoactive properties of Banisteriopsis capi, an ingredient of famous hallucinogenic drink „ayahuasca“, and Peganum harmala, the traditional herbal remedy as emmenagogue & abortifacient, have been linked to inhibition of monoamine oxidases (MAO-A & B) by their beta-carboline harmala alkaloid constituents. Due to central role of MAOs in the metabolism of dietary as well as neurotransmitters metabolism, these enzymes represent attractive drug targets in the pharmacological therapy of neurodegenerative diseases and depression. A series of beta-carboline analogs were assayed in vitro as inhibitors of recombinant human MAO-A and MAO-B isoforms. The analogs were tested at saturating and varying concentrations of the substrates for evaluation of kinetic characteristics of inhibition of specific enzyme isoform. Most of the compounds showed more potent and selective inhibition of MAO-A. A few beta-carboline analogs, selective against MAO-B, were also identified. The results have been further analyzed for structure activity relationship and should be useful in designing the MAO inhibitors with desired therapeutic characteristics. Recent efforts toward the development of MAO inhibitors are focused on selective MAO-A or MAO-B inhibitors. Selective MAO-A inhibitors are effective in the treatment of depression whereas MAO-B inhibitors are useful for the treatment of Alzheimer's disease and Parkinson's disease. Acknowledgements: Supported by the National Center for Complementary and Alternative Medicine (NCCAM), National Institute of Health, Grant No. 5R21AT003409–02.